CLINICAL RESEARCH: A network of GP surgeries around Bath has been selected as the site of a clinical trial for a diabetes drug from the pharmaceutical giant Pfizer.
The trial of ertugliflozin, a drug for treating type 2 diabetes, will take place across eight surgeries with around 15-20 expected participants.
The Bath Area Research Organisation Network, which includes eight GP practices in Bath and Wiltshire, will take part in the trial.
The practices involved in the trial will liaise with one another through the use of GP investigators, local primary care clincians who will monitor the condition of patients taking part in the trials.
The trials are planned to start in summer 2015, with no end date yet confirmed.
Patient governance approval for both commisioners goes through the research and development office at Bath University.
Pfizer press statement (attached) and HSJ reporting
29 September 2014